Chi Van Dang
Directeur/Membre du Conseil chez Cornerstone Pharmaceuticals, Inc.
Profil
Chi Van Dang currently works at Cornerstone Pharmaceuticals, Inc., as Director and Ludwig Institute for Cancer Research Ltd., as Director.
Postes actifs de Chi Van Dang
| Sociétés | Poste | Début |
|---|---|---|
Cornerstone Pharmaceuticals, Inc.
 Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Directeur/Membre du Conseil | - |
Ludwig Institute for Cancer Research Ltd.
 Ludwig Institute for Cancer Research Ltd. Medical/Nursing ServicesHealth Services Ludwig Institute For Cancer Research Ltd. is non-profit organization engages in the prevention and control of cancer through researches, integrated laboratory and clinical trials. The firm operates in the areas of cell biology, genomics, immunology, neuroscience, signaling, stem cells, therapeutic, tumor biology, brain and breast cancer, immunotherapy, and melanoma. The company was founded by Daniel K. Ludwig in 1971 and is headquartered in New York, NY. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Commercial Services |
Ludwig Institute for Cancer Research Ltd.
Ludwig Institute for Cancer Research Ltd. Medical/Nursing ServicesHealth Services Ludwig Institute For Cancer Research Ltd. is non-profit organization engages in the prevention and control of cancer through researches, integrated laboratory and clinical trials. The firm operates in the areas of cell biology, genomics, immunology, neuroscience, signaling, stem cells, therapeutic, tumor biology, brain and breast cancer, immunotherapy, and melanoma. The company was founded by Daniel K. Ludwig in 1971 and is headquartered in New York, NY. | Health Services |
